Correlation analysis of colorectal cancer patients serum CA19-9, CEA, TPS level with clinicopathology

doi:10.3877/cma.j.issn.2095-3224.2013.05.06.

Abstract

Abstract:

Objective

To assess the correlation of colorectal cancer patients’ preoperative serum CA19-9, TPS, CEA levels with patients’ age, gender, tumors’ differentiation, location, depth of invasion, lymph node metastasis, distant metastasis and TNM stages etc.

Method

Retrospectively analyze clinical and pathological data of 615 colorectal cancer patients who underwent operations in Chinese Academy of Medical Sciences Cancer Hospital in 2010 applying χ² test and t-test.

Results

Serum CA19-9 and CEA level were of greater significances in preoperative staging for patients with colorectal cancer, and could predict the depth of tumor invasion, lymph node metastasis, and vascular invasion, so as to predict the prognosis.And compared with value, positive rate is more valuable.For early stage(0, Ι period)patients, TPS positive rate is significantly higher than the other two markers, so it is more sensitive for the early detection of the disease.Combined application can significantly improve the detection rate of the disease.

Conclusion

Preoperative serum CEA, CA19-9 and TPS levels of colorectal cancer patients contribute to preoperative staging and prognosis predicting, and should be routinely examined and combinedly applied.

Key words: Colorectal neoplasms, Neoplasm staging, Antigens, tumor-associated, carbohydrate, Carcinoembryonic antigen

Xi LIU, Qian LIU. Correlation analysis of colorectal cancer patients serum CA19-9, CEA, TPS level with clinicopathology[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2013, 02(05): 230-233.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjzcjbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3224.2013.05.06.

https://zhjzcjbdzzz.cma-cmc.com.cn/EN/Y2013/V02/I05/230

Figures/Tables 2

References 8

[1]	Ahmedin Jemal，Freddie Bray，Melissa M，et al.Global cancer statistics.CA Cancer J Clin，2011,61(2):69-90.
[2]	王影，梁欢．血清CEA、CA199、CA242联检在大肠癌诊断中的临床应用．中国卫生检验杂志，2008,18(7):1359-1360.
[3]	何静，范小华，罗湛滨，等.439例大肠癌血清CEA水平的临床分析．医学临床研究，2008,25(10):1787-1788.
[4]	刘传，清水汪，王宁，等．结直肠癌术前血清CEA、CA199表达水平与临床病理关系的研究．医学研究杂志，2012,14(3):27-30.
[5]	Tarantino I，Warschkow R，Worni M，et al.Elevated preoperative CEA is associated with worse survival in stage I-III rectal cancer patients.Br J Cancer，2012,107(2):266-274.
[6]	Uehara M，Manaka D，Baba S et al.Prognostic study of preoperative serum levels of CEA and CA 19-9 in colorectal cancer.Gan To Kagaku Ryoho，2007,34(9):1413-1417.
[7]	武春梅，蒋潮涌，吕先鱼，等．结直肠癌患者血清CEA、CA199水平与临床病理因素及预后的关系．中国医学创新，2012,9(29):38-39.
[8]	Katoh H，Yamashita K，Kokuba Y，et al.Diminishing impact of preoperative carcinoembryonicantigen(CEA)in Prognosis of Dukes’ C colorectal cancer.ANTICANCER RESEARCH，2008,28(3B):1933-1941.

变量		例数	CA19-9水平(±s)	P值	TPS水平(±s)	P值	CEA水平(±s)	P值
年龄		?	?	?	?	?	?	?
?	<60	289	102±1062	0.715	155±548	0.533	13±45	0.260
?	>60	326	130±872	0.715	134±196	0.533	28±210	0.260
性别		?	?	?	?	?	?	?
?	男	364	98±976	0.561	136±205	0.588	14±42	0.214
?	女	251	144±952	0.561	154±577	0.588	30±238	0.214
肿瘤位置		?	?	?	?	?	?	?
?	直肠	359	121±1169	0.931	147±494	0.849	12±36	0.087
?	结肠	249	114±576	0.931	141±203	0.849	34±241	0.087
?	左半	130	105±614	0.797	127±190	0.269	46±327	0.413
?	右半	119	123±534	0.797	156±216	0.269	21±67	0.413
淋巴结转移		?	?	?	?	?	?	?
?	无	321	49±346	0.068	115±135	0.068	22±208	0.834
?	有	294	191±1347	0.068	175±559	0.068	20±60	0.834
肿瘤分化程度		?	?	?	?	?	?	?
?	低	128	401±2031	0.001	246±817	0.002	23±75	0.920
?	中、高	452	45±293	0.001	118±156	0.002	22±177	0.920
脉管瘤栓		?	?	?	?	?	?	?
?	无	543	59±376	0.001	120±155	0.001	20±163	0.635
?	有	72	558±2616	0.001	327±1084	0.001	29±76	0.635
TNM分期		?	?	?	?	?	?	?
?	0期	14	18±12	?	98±96	?	2.1±1.1	?
?	Ⅰ期	85	11±10	0.025	98±93	0.993	2.5±1.9	0.382
?	Ⅱ期	208	25±51	0.018	121±152	0.192	11±36	0.034
?	Ⅲ期	254	87±464	0.056	110±104	0.366	12±45	0.669
?	Ⅳ期	54	817±3061	0.001	485±1282	0.001	133±500	0.001

变量		例数	CA19-9水平(±s)	P值	TPS水平(±s)	P值	CEA水平(±s)	P值
年龄		?	?	?	?	?	?	?
?	<60	289	102±1062	0.715	155±548	0.533	13±45	0.260
?	>60	326	130±872	0.715	134±196	0.533	28±210	0.260
性别		?	?	?	?	?	?	?
?	男	364	98±976	0.561	136±205	0.588	14±42	0.214
?	女	251	144±952	0.561	154±577	0.588	30±238	0.214
肿瘤位置		?	?	?	?	?	?	?
?	直肠	359	121±1169	0.931	147±494	0.849	12±36	0.087
?	结肠	249	114±576	0.931	141±203	0.849	34±241	0.087
?	左半	130	105±614	0.797	127±190	0.269	46±327	0.413
?	右半	119	123±534	0.797	156±216	0.269	21±67	0.413
淋巴结转移		?	?	?	?	?	?	?
?	无	321	49±346	0.068	115±135	0.068	22±208	0.834
?	有	294	191±1347	0.068	175±559	0.068	20±60	0.834
肿瘤分化程度		?	?	?	?	?	?	?
?	低	128	401±2031	0.001	246±817	0.002	23±75	0.920
?	中、高	452	45±293	0.001	118±156	0.002	22±177	0.920
脉管瘤栓		?	?	?	?	?	?	?
?	无	543	59±376	0.001	120±155	0.001	20±163	0.635
?	有	72	558±2616	0.001	327±1084	0.001	29±76	0.635
TNM分期		?	?	?	?	?	?	?
?	0期	14	18±12	?	98±96	?	2.1±1.1	?
?	Ⅰ期	85	11±10	0.025	98±93	0.993	2.5±1.9	0.382
?	Ⅱ期	208	25±51	0.018	121±152	0.192	11±36	0.034
?	Ⅲ期	254	87±464	0.056	110±104	0.366	12±45	0.669
?	Ⅳ期	54	817±3061	0.001	485±1282	0.001	133±500	0.001

变量		例数	CA19-9阳性率(%)	P值	TPS阳性率(%)	P值	CEA阳性率(%)	P值	联合检测阳性率(%)	P值
年龄		?	?	?	?	?	?	?	?	?
?	<60	289	16.3	0.362	31.4	0.352	30.7	0.033	52.6	0.015
?	>60	326	19.1	0.362	35.0	0.352	38.9	0.033	62.3	0.015
性别		?	?	?	?	?	?	?	?	?
?	男	364	15.7	0.101	34.9	0.315	33.1	0.241	58.0	0.883
?	女	251	20.8	0.101	31.0	0.315	37.8	0.241	57.4	0.883
肿瘤位置		?	?	?	?	?	?	?	?	?
?	直肠	359	14.5	0.011	29.4	0.011	33.0	0.234	55.6	0.178
?	结肠	249	22.5	0.011	39.5	0.011	37.7	0.234	61.0	0.178
?	左半	130	16.2	0.012	33.1	0.030	34.9	0.348	56.2	0.098
?	右半	119	29.4	0.012	46.8	0.030	40.7	0.348	66.4	0.098
淋巴结转移		?	?	?	?	?	?	?	?	?
?	无	321	11.5	0.001	30.5	0.131	25.3	0.001	48.3	0.001
?	有	294	24.6	0.001	36.4	0.131	45.7	0.001	68.0	0.001
肿瘤分化程度		?	?	?	?	?	?	?	?	?
?	低	128	27.6	0.002	40.8	0.054	42.2	0.115	69.5	0.005
?	中、高	452	15.7	0.002	31.6	0.054	34.6	0.115	55.8	0.005
脉管瘤栓		?	?	?	?	?	?	?	?	?
?	无	542	15.5	0.001	32.0	0.057	33.4	0.021	54.9	0.001
?	有	72	35.2	0.001	43.5	0.057	47.2	0.021	79.2	0.001
TNM分期		?	?	?	?	?	?	?	?	?
?	0期	14	7.1	?	21.4	?	0.0	?	28.6	?
?	Ⅰ期	85	2.4	0.370	23.8	1.000	9.5	0.597	30.6	1.000
?	Ⅱ期	208	12.0	0.009	33.5	0.110	30.3	0.000	54.3	0.000
?	Ⅲ期	254	18.9	0.044	31.6	0.665	42.2	0.008	64.2	0.032
?	Ⅳ期	54	62.3	0.000	60.0	0.000	68.5	0.000	90.7	0.000

变量		例数	CA19-9阳性率(%)	P值	TPS阳性率(%)	P值	CEA阳性率(%)	P值	联合检测阳性率(%)	P值
年龄		?	?	?	?	?	?	?	?	?
?	<60	289	16.3	0.362	31.4	0.352	30.7	0.033	52.6	0.015
?	>60	326	19.1	0.362	35.0	0.352	38.9	0.033	62.3	0.015
性别		?	?	?	?	?	?	?	?	?
?	男	364	15.7	0.101	34.9	0.315	33.1	0.241	58.0	0.883
?	女	251	20.8	0.101	31.0	0.315	37.8	0.241	57.4	0.883
肿瘤位置		?	?	?	?	?	?	?	?	?
?	直肠	359	14.5	0.011	29.4	0.011	33.0	0.234	55.6	0.178
?	结肠	249	22.5	0.011	39.5	0.011	37.7	0.234	61.0	0.178
?	左半	130	16.2	0.012	33.1	0.030	34.9	0.348	56.2	0.098
?	右半	119	29.4	0.012	46.8	0.030	40.7	0.348	66.4	0.098
淋巴结转移		?	?	?	?	?	?	?	?	?
?	无	321	11.5	0.001	30.5	0.131	25.3	0.001	48.3	0.001
?	有	294	24.6	0.001	36.4	0.131	45.7	0.001	68.0	0.001
肿瘤分化程度		?	?	?	?	?	?	?	?	?
?	低	128	27.6	0.002	40.8	0.054	42.2	0.115	69.5	0.005
?	中、高	452	15.7	0.002	31.6	0.054	34.6	0.115	55.8	0.005
脉管瘤栓		?	?	?	?	?	?	?	?	?
?	无	542	15.5	0.001	32.0	0.057	33.4	0.021	54.9	0.001
?	有	72	35.2	0.001	43.5	0.057	47.2	0.021	79.2	0.001
TNM分期		?	?	?	?	?	?	?	?	?
?	0期	14	7.1	?	21.4	?	0.0	?	28.6	?
?	Ⅰ期	85	2.4	0.370	23.8	1.000	9.5	0.597	30.6	1.000
?	Ⅱ期	208	12.0	0.009	33.5	0.110	30.3	0.000	54.3	0.000
?	Ⅲ期	254	18.9	0.044	31.6	0.665	42.2	0.008	64.2	0.032
?	Ⅳ期	54	62.3	0.000	60.0	0.000	68.5	0.000	90.7	0.000

[1]	Xia Kang, Hao Tian, Jin Qian, Yuan Gao, Hongming Miao, Xiaowei Qi. Osteorin attenuates osteolysis during bone metastasis of cancers through inhibiting osteoclastogenesis [J]. Chinese Journal of Breast Disease(Electronic Edition), 2023, 17(06): 329-339.
[2]	Dechen Wang, Kang Yang, Zijie Yang, Mingbin Gui, Lianping Qu, Xiaofeng Zhang, Feng Gao. Progress of microsatellite stability state and PD-1/PD-L1/IDO in colorectal carcinoma [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(06): 462-465.
[3]	Jia Fu, Haimin Xiao, Xi Wu, Tao Feng, Shuai Shi. Value of age-adjusted Charlson comorbidity index in assessing perioperative complications for laparoscopic colorectal cancer [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(05): 336-341.
[4]	Xu Tang, Bing Han, Wei Liu, Ruxing Chen. Analysis of risk factors for metachronous liver metastases after radical colorectal cancer surgery and construction of a predictive model [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(01): 16-20.
[5]	Shengjun Zhang, Ajing Zhao, Shoubo Li, Xianghong Hao, Minli Liu. An experimental study on the promotion of colorectal cancer invasion and migration by high glucose through HGF/c-met pathway [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(01): 21-24.
[6]	Ting Li, Lin Zhang. Relationship between serum fatty acid metabolites and vitamin D levels and colorectal cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(06): 661-665.
[7]	Wenkai Ni, Chong Qi, Xiaodan Xu, Xiecheng Zhou, Qingzhang Yin, Yuankun Cai. Analysis of influencing factors of prolonged postoperative ileus in patients with colorectal cancer after operation [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(06): 484-489.
[8]	Xiaoyu Fan, Sizheng Sun, Yimin E, Chunzhao Yu. Different surgical options for obstructive left colon cancer [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(06): 500-504.
[9]	Xu Guan, Xishan Wang. Reflecting on the merits and demerits of regional lymph node management in colorectal cancer based on surgical and immune perspectives [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(06): 448-452.
[10]	Ruiqi Gu, Hongsheng Fang, Guoxiang Cai. Application and progress of circulating tumor DNA detection technology in the diagnosis and treatment of colorectal cancer [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(06): 453-459.
[11]	Yicheng Huang, Chen Lu, Sizheng Sun, Chunzhao Yu. Expression of liver-specific transcription factors FOXA2 in human stepwise metastatic colorectal carcinoma model and its significance [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(05): 396-403.
[12]	Qi Liu, Kai Zhang, Jiannan Li, Tongjun Liu. Current status and progress of biologic treatment for colorectal cancer liver metastases [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(05): 415-419.
[13]	Yin Wu, Zhiqin Chen, Yong Gao, Ming Quan. Progress in diagnosis and treatment of Her-2 positive colorectal cancer [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(05): 420-425.
[14]	Boyang Fan, Ning Wang, Qian Zhang, Guiyu Wang. The progress in research of molecular mechanism of circRNAs regulating colorectal cancer metastasis [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(05): 426-430.
[15]	Xin Sun, Haibo Cheng, Weixing Shen. Curative effect mechanism of Xianlian Jiedu decoction in treatment of patients with stage Ⅲ colorectal cancer based on transcriptomics [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(05): 277-283.

Please choose a citation manager

Content to export